tbuckley/cabot-search huggingface dataset:
Brief hospitalization: a two-year follow-up
Authors: M I Herz, J Endicott, R L Spitzer
Journal: American Journal of Psychiatry (1977)

The author present two-year follow-up data of a controlled study of 175 newly admitted inpatients who lived with families, comparing the relative efficacy of brief hospitalization (with and without transitional day care) and standard hospitalization (with all patients offered outpatient aftercare). The long-term results confirm the preliminary finding that brief hospitalization is preferable to longer term hospitalization for most patients. Briefly hospitalized patients spent significantly less time as inpatients and showed less psychopathology and impairment in role functioning. In contrast to preliminary findings, the long-term results indicate that use of day care reduced the number of inpatient days.
Case 40-1986
Authors: Richard C. Cabot, Robert E. Scully, Eugene J. Mark, Betty U. McNeely, William E. Strole, Carolyn C. Compton
Journal: New England Journal of Medicine (1986)

Presentation of CaseA 28-year-old woman was admitted to the hospital because of fever and ascites.The patient was apparently well until two weeks earlier, when she had a fever and sore throat. A physician prescribed erythromycin, which was discontinued by the patient after two days. Eight days before admission she was seen at another facility because of fever, nausea, vomiting, and abdominal swelling. On examination the temperature was 38.9°C. General physical examination was negative. The abdomen was soft and tympanitic, and no evidence of ascites was found. Pelvic examination revealed no discharge or tenderness on digital movement of the . . .
Reducing Flightless I expression decreases severity of psoriasis in an imiquimod-induced murine model of psoriasiform dermatitis
Authors: H.T. Chong, G.N. Yang, S. Sidhu, J. Ibbetson, Z. Kopecki, A.J. Cowin
Journal: British Journal of Dermatology (2016)

Psoriasis is a common chronic skin condition characterized by excessive inflammation and aberrant epidermal proliferation. Flightless I (Flii) is an actin-remodelling protein that regulates these processes, suggesting a possible role in psoriasis.We sought to determine whether a benefit in psoriasiform dermatitis might occur after modulating Flii gene expression or reducing its levels using neutralizing antibodies.Biopsies of psoriatic skin lesions from patients were assessed for Flii levels. Psoriasis-like lesions were induced in Flii heterozygous (Flii+/- ), wild-type (Flii+/+ ) and Flii transgenic (FliiTg/Tg ) mice using topical application of imiquimod. Additionally, psoriasis-induced wild-type mice were treated with topical application of Flii neutralizing antibodies and erythema, inflammation and histology were assessed.Flii was elevated in psoriatic lesions from patients with psoriasis compared with normal human skin. Reducing Flii decreased erythema, inflammatory cell infiltrate, proinflammatory cytokines and the thickness of the epidermis. Topical application of Flii neutralizing antibodies to wild-type mice treated with imiquimod resulted in significantly reduced psoriasiform dermatitis.Flii is a novel target involved in psoriasiform dermatitis and reducing cutaneous Flii could potentially be a new approach for treating patients with psoriasis.
GMC review of fitness to practise procedures is complete
Authors: Anna Rowland
Journal: BMJ (2016)

McCartney criticises the impact of the GMC’s fitness to practise procedures on vulnerable doctors,1 but she may not know that we have concluded the review that we commissioned Prof Louis Appleby to oversee.

We are very grateful for Prof Appleby’s time and commitment in this review. His expertise enabled us to produce a comprehensive set …
Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma following autologous stem cell transplant: A cost-effectiveness analysis updated with 5-year follow-up data from the pivotal trial.
Authors: Christopher Parker, Gemma Kay, Esprit Ma, Beth Woods, James Eaton, Peter Sajosi, Andreas Engstrom, Ross Selby, Eugene Benson, Jeremy Teasell, Akshara Richhariya, Andrew Briggs, Vijayveer Bonthapally
Journal: Journal of Clinical Oncology (2016)

19 Background: In 2015, the Scottish Medicines Consortium (SMC) made a positive recommandation for brentuximab vedotin (BV) in patients with relapsed or refractory (R/R) Hodgkin lymphoma (HL) who have received autologous stem cell transplantation (ASCT) based on 3-year follow-up data from the pivotal phase 2 single-arm trial (SG035-0003; NCT00848926). At 3-years, the incremental cost-effectiveness ratio (ICER) for brentuximab vedotin compared with chemotherapy +/- radiotherapy (C/R) was £43,731 per quality-adjusted life year (QALY). This study re-evaluated the cost-effectiveness analysis with 5-year follow-up data from the pivotal trial. Methods: A partitioned survival model was developed using a Scottish health system perspective over a lifetime time-horizon. Three health states were evaluated: progression-free survival (PFS), post-progression survival, and death. The relevant comparators were C/R, or C/R with intent to allogeneic stem cell transplantation. Clinical outcomes (PFS and overall survival [OS]) for BV were estimated based on data from the pivotal trial in 102 patients. A naïve comparison with the specified comparators was conducted using published survival data. ICERs were calculated with measures of the clinical outcomes, direct costs and QALYs. Deterministic and probabilistic sensitivity analyses were conducted to evaluate the robustness of the model. Results: The 5-year follow-up data reduced the base case ICER for BV from £43,731 to £38,769 per QALY versus C/R and increased the probability of cost-effectiveness. The variation in ICER for BV generated by the deterministic sensitivity analyses was also reduced resulting from reduced uncertainty in the estimation of long term clinical outcomes. Conclusions: This update has strengthened the cost-effectiveness evidence for BV in patients with R/R HL post-ASCT. The 5-year follow-up has reduced the uncertainty in the long term outcomes and reduced the ICER, which is low in comparison to other treatments for orphan diseases approved by UK agencies. BV may therefore represent a cost-effective treatment option for this patient group.
Zosteriform Secondary Cutaneous Diffuse Large B-Cell Lymphoma on FDG PET/CT
Authors: Chiung-Wei Liao, Kuo-Yang Yen, Te-Chun Hsieh, Chia-Hung Kao
Journal: Clinical Nuclear Medicine (2016)

We present a case of a woman who had erythematous papules on the abdomen accompanied with numbness and local heat sensation. She had received chemotherapy for advanced follicular lymphoma. 18F-FDG PET/CT demonstrated band-like hypermetabolic lesions seemingly involving dermatomes of lower abdominal wall, which was confirmed as secondary cutaneous diffuse large B-cell lymphoma via skin biopsy.
Familial Mastocytosis: Identification Of KIT K509I Mutation and Its In Vitro Sensitivity To Imatinib, Dasatinib and PKC412
Authors: Paula De Melo Campos, João Agostinho Machado-Neto, Adriana Silva Santos Duarte, Renata Scopim-Ribeiro, Flavia Fonseca de Carvalho Barra, José Vassallo, Irene Lorand-Metze, Ramon V. Tiu, Fernando Ferreira Costa, Sara T O Saad, Fabiola Traina
Journal: Blood (2013)
Mucosal Cyst of the Maxillary Sinus
Authors: W A van der Kwast, I van der Waal
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Outcome measures in trials of systemic therapy for advanced prostate cancer: A systematic review.
Authors: Michael John Fabricius, Angela Cottrell, Rahul Gujadhur, Ala'a Sharaf, Robert Pickard, Elaine McColl
Journal: Journal of Clinical Oncology (2015)

e16126 Background: Selection of outcome measures is central to effective trial design. Guidelines from regulatory bodies (FDA, EMA) indicate that investigators should demonstrate improvement in survival or quality of life (QoL) for a drug to be licensed for advanced prostate cancer (PC). Methods: We searched Medline, Embase, Cochrane Register of Controlled Trials and PsycINFO databases using terms to identify castrate resistant and metastatic prostate cancer, combined with validated filters for identifying randomized control trials (RCTs). The search period was 2008 to 2013. The results were screened in duplicate by independent blinded reviewers against the following criteria: randomized control trials, > 50 participants, castrate-resistant or metastatic PC, systemic therapy. We extracted data relating to the trial populations, interventions and outcomes from the selected full text articles. Trials were assessed for quality using the Cochrane risk of bias tool, and the ISOQoL checklist for patient-reported outcome (PRO) data. Results: 3187 citations were retrieved. Following abstract screening 286 articles were selected for full-text review. 62 papers describing 47 trials with a total of 24656 participants were included in the analysis. Of the 28 phase 3 (P3) trials, 21 enrolled patients with castrate resistant PC and 26 enrolled patients with metastases. Ten different primary outcome measures were used in the 28 P3 trials. Overall survival (OS) was the primary outcome in 15/28 trials. 12/28 trials had a primary outcome relating to disease progression, although this was defined in 9 different ways. Overall, disease progression was measured in 18 different ways in the 47 included trials. There were 35 different secondary endpoints used in the P3 trials; the median number used was 3.5 (range 0-9). QoL was the co-primary endpoint in 2/28 P3 trials. QoL was a secondary endpoint in 12/28 P3 trials and 12/19 P2 trials. 11 different PRO instruments were used to measure QoL or pain outcomes. Conclusions: The reporting of advanced PC trials is highly heterogenous despite published guidance. QoL is reported in less than half of trials despite the palliative nature of treatment, and the methods of reporting QoL are inconsistent.
Vaccine Pricing and US Immunization Policies
Authors: Jason L. Schwartz
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
P2-150: Marked decline of TARSH gene expression in primary lung cancer
Authors: Kunihiko Terauchi, Junichi Shimada, Natsuko Uekawa, Kazuhiro Ito, Masashi Yanada, Masanori Shimomura, Takeshi Yaoi, Mitsuo Maruyama, Shinji Fushiki
Journal: Journal of Thoracic Oncology (2007)
c-Myc Alteration Determines the Therapeutic Response to FGFR Inhibitors
Authors: Hongyan Liu, Jing Ai, Aijun Shen, Yi Chen, Xinyi Wang, Xia Peng, Hui Chen, Yanyan Shen, Min Huang, Jian Ding, Meiyu Geng
Journal: Clinical Cancer Research (2016)

Abstract Purpose: Lately, emerging evidence has suggested that oncogenic kinases are associated with specific downstream effectors to govern tumor growth, suggesting potential translational values in kinase-targeted cancer therapy. Tyrosine kinase FGFR, which is aberrant in various cancer types, is one of the most investigated kinases in molecularly targeted cancer therapy. Herein, we investigated whether there exists key downstream effector(s) that converges FGFR signaling and determines the therapeutic response of FGFR-targeted therapy. Experimental Design: A range of assays was used to assess the role of c-Myc in FGFR aberrant cancers and its translational relevance in FGFR-targeted therapy, including assessment of drug sensitivity using cell viability assay, signaling transduction profiling using immunoblotting, and in vivo antitumor efficacy using cancer cell line–based xenografts and patient-derived xenografts models. Results: We discovered that c-Myc functioned as the key downstream effector that preceded FGFR-MEK/ERK signaling in FGFR aberrant cancer. Disruption of c-Myc overrode the cell proliferation driven by constitutively active FGFR. FGFR inhibition in FGFR-addicted cancer facilitated c-Myc degradation via phosphorylating c-Myc at threonine 58. Ectopic expression of undegradable c-Myc mutant conferred resistance to FGFR inhibition both in vitro and in vivo. c-Myc level alteration stringently determined the response to FGFR inhibitors, as demonstrated in FGFR-responsive cancer subset, as well as cancers bearing acquired or de novo resistance to FGFR inhibition. Conclusions: This study reveals a stringent association between FGFR and the downstream effector c-Myc in FGFR-dependent cancers, and suggests the potential therapeutic value of c-Myc in FGFR-targeted cancer therapy. Clin Cancer Res; 23(4); 974–84. ©2016 AACR.
Mammalian Chromosomes &lt;italic&gt;in Vitro&lt;/italic&gt;. IV. Some Human Neoplasms&lt;xref ref-type="fn" rid="fn1"&gt;2&lt;/xref&gt;
Authors: T. C. Hsu
Journal: JNCI Journal of the National Cancer Institute (1954)

Journal Article Mammalian Chromosomes in Vitro. IV. Some Human Neoplasms Get access T. C. Hsu T. C. Hsu Tissue Culture Laboratory, University of Texas, Medical Branch, Galveston, Texas Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 14, Issue 4, February 1954, Pages 905–933, https://doi.org/10.1093/jnci/14.4.905 Published: 01 February 1954 Article history Received: 10 August 1953 Published: 01 February 1954
Case 37-1973
Authors: Richard C. Cabot, Benjamin Castleman, Robert E. Scully, Betty U. McNeely, Leslie W. Ottinger, James J. Galdabini
Journal: New England Journal of Medicine (1973)

Presentation of CaseA 56-year-old woman was admitted to the hospital because of azotemia.She was well until 13 days previously, when she was severely injured in an automobile accident. On admission to another hospital the blood pressure was not obtainable. She was found to have fractures of all 12 right ribs, with a flail right hemithorax, a scalping injury, a large, dirty laceration of the right vastus lateralis and an extensive avulsion injury of the right arm. The right clavicle was fractured, and the left patella shattered. Cardiac arrest occurred, and she was resuscitated. A right tube thoracostomy and . . .
Telemedicine in Heart Failure—Ineffective or Just Ill Used?—Reply
Authors: Michael K. Ong, Patrick S. Romano, Gregg C. Fonarow
Journal: JAMA Internal Medicine (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Massive Rectal Hemorrhage After Prostate Biopsy
Authors: Justin C. Laracy, Ricky Regalbuto, Brian L. Block
Journal: JAMA Internal Medicine (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
US food subsidies fuel obesity, study finds
Authors: Michael McCarthy
Journal: BMJ (2016)

US adults who ate more foods that benefited from federal agricultural subsidies were at higher risk of obesity, elevated cholesterol, and other risk factors for cardiovascular disease, a study has found.1

Although US dietary guidelines recommend limited consumption of saturated fats, sugars, salt, and refined grains, a large proportion of federal agricultural subsidies support the production of soybeans, rice, sorghum, dairy, and livestock commodities that are often converted into high fat meat and dairy products, processed and packaged foods, refined grains, …
Letter to the editor: Is a reduced duration of post-discharge surgical site infection surveillance really in our best interests?
Authors: B M Davies, H C Patel
Journal: Eurosurveillance (2015)

Preview this article: Letter to the editor: Is a reduced duration of post-discharge surgical site infection surveillance really in our best interests?, Page 1 of 1 < Previous page | Next page > /docserver/preview/fulltext/eurosurveillance/20/13/art21081-en-1.gif
The Coding Genome of Nodal Marginal Zone Lymphoma Reveals Recurrent Molecular Alterations of PTPRD and Other Jak/Stat Signaling Genes
Authors: Valeria Spina, Hossein Khiabanian, Alessio Bruscaggin, Monica Messina, Sara Monti, Antony B. Holmes, Sabina Chiaretti, Rosella Famà, Luca Arcaini, Marco Lucioni, Fabrizio Tabbò, Stefania Cresta, Silvia Rasi, Sakellarios Zairis, Antonio Ramponi, Roberto Marasca, Maurilio Ponzoni, Enrico Tiacci, Brunangelo Falini, Francesco Bertoni, Laura Pasqualucci, Robin Foà, Giorgio Inghirami, Raul Rabadan, Gianluca Gaidano, Davide Rossi
Journal: Blood (2014)
Alternatives to carbapenems in ventilator-associated pneumonia due to ESBL-producing Enterobacteriaceae
Authors: A. Boucher, A. Meybeck, P. Patoz, M. Valette, D. Thellier, P.Y. Delannoy, A. Chiche, N. Boussekey, H. Georges, O. Leroy
Journal: Journal of Infection (2016)
Limited value of whole blood Xpert® MTB/RIF for diagnosing tuberculosis in children
Authors: Christian Pohl, Liliana K Rutaihwa, Frederick Haraka, Martin Nsubuga, Francesco Aloi, Nyanda E Ntinginya, Daniel Mapamba, Norbert Heinrich, Michael Hoelscher, Ben J Marais, Levan Jugheli, Klaus Reither
Journal: Journal of Infection (2016)

We evaluated the ability of the Xpert(®) MTB/RIF assay to detect Mycobacterium tuberculosis in whole blood of children with tuberculosis in tuberculosis endemic settings with high rates of HIV infection.From June 2011 to September 2012 we prospectively enrolled children with symptoms or signs suggestive of tuberculosis at three research centres in Tanzania and Uganda. After clinical assessment, respiratory specimens were collected for microscopy and culture, as well as whole blood for Xpert(®) MTB/RIF. Children were classified according to standardised case definitions.A total of 232 children were evaluated; 14 (6.0%) had culture-confirmed tuberculosis. The Xpert(®) MTB/RIF assay detected M. tuberculosis in 5/232 (2.2%) blood samples with 1 (0.4%) error reading and presumably 1 (0.4%) false-positive result. The sensitivity of the assay in children with culture-confirmed (1/14) versus no tuberculosis (1/117) was 7.1% (95% CI, 1.3-31.5). Three of the five Xpert(®) MTB/RIF positive patients had negative cultures, but were classified as probable tuberculosis cases. Assay sensitivity against a composite reference standard (culture-confirmed, highly probable or probable tuberculosis) was 5.4% (95% CI, 2.1-13.1).Whole blood Xpert(®) MTB/RIF demonstrated very poor sensitivity, although it may enhance the diagnostic yield in select cases, with culture-negative tuberculosis.